HbA1c treatment effect

Propensity score matching

Overall population (n=10810)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1012)

3–5 mmol/mol (n=1262)

0–3 mmol/mol (n=3380)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=2988)

3–5 mmol/mol (n=1368)

>5 mmol/mol (n=800)

−12 −10 −8 −6 −4 −2 0 2 4 6 8 10 12 14
Average treatment effect (mmol/mol)

Propensity score matching + adjust

Overall population (n=10810)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1012)

3–5 mmol/mol (n=1262)

0–3 mmol/mol (n=3380)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=2988)

3–5 mmol/mol (n=1368)

>5 mmol/mol (n=800)

−12 −10 −8 −6 −4 −2 0 2 4 6 8 10 12 14
Average treatment effect (mmol/mol)

Adjust

Overall population (n=28685)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2193)

3–5 mmol/mol (n=2853)

0–3 mmol/mol (n=8741)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=9064)

3–5 mmol/mol (n=3778)

>5 mmol/mol (n=2056)

−12 −10 −8 −6 −4 −2 0 2 4 6 8 10 12 14
Average treatment effect (mmol/mol)

Weight change

Propensity score matching

■ SGLT2 ■ GLP1

Overall population (n=16280)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1531)

3–5 mmol/mol (n=1878)

0–3 mmol/mol (n=5150)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=4629)

3–5 mmol/mol (n=1926)

>5 mmol/mol (n=1166)

Predicted weight change (kg)

Propensity score matching + adjusted

■ SGLT2 ■ GLP1

Overall population (n=16280)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1531)

3–5 mmol/mol (n=1878)

0–3 mmol/mol (n=5150)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=4629)

3–5 mmol/mol (n=1926)

>5 mmol/mol (n=1166)

Predicted weight change (kg)

Adjusted

■ SGLT2 ■ GLP1

Overall population (n=41728)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3152)

3–5 mmol/mol (n=4196)

0–3 mmol/mol (n=12935)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=13231)

3–5 mmol/mol (n=5300)

>5 mmol/mol (n=2914)

Predicted weight change (kg)

eGFR change

Propensity score matching

■ SGLT2 ■ GLP1

Overall population (n=16618)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1540)

3–5 mmol/mol (n=1936)

0–3 mmol/mol (n=5176)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=4720)

3–5 mmol/mol (n=1970)

>5 mmol/mol (n=1276)

Predicted eGFR change

Propensity score matching + adjusted

■ SGLT2 ■ GLP1

Overall population (n=16618)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1540)

3–5 mmol/mol (n=1936)

0–3 mmol/mol (n=5176)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=4720)

3–5 mmol/mol (n=1970)

>5 mmol/mol (n=1276)

Predicted eGFR change

Adjusted

■ SGLT2 ■ GLP1

Overall population (n=44339)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3334)

3–5 mmol/mol (n=4405)

0–3 mmol/mol (n=13601)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=13990)

3–5 mmol/mol (n=5758)

>5 mmol/mol (n=3251)

Predicted eGFR change

Discontinuation

Propensity score matching

■ SGLT2 ■ GLP1

Overall population (n=30992)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3043, event = 459)

3–5 mmol/mol (n=3595, event = 562)

0–3 mmol/mol (n=9545, event = 1548)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=8672, event = 1556)

3–5 mmol/mol (n=3577, event = 689)

>5 mmol/mol (n=2560, event = 601)

Discontinuation (%)

Propensity score matching + adjusted

■ SGLT2 ■ GLP1

Overall population (n=30992)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3043, event = 459)

3–5 mmol/mol (n=3595, event = 562)

0–3 mmol/mol (n=9545, event = 1548)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=8672, event = 1556)

3–5 mmol/mol (n=3577, event = 689)

>5 mmol/mol (n=2560, event = 601)

Discontinuation (%)

Adjusted

■ SGLT2 ■ GLP1

Overall population (n=77741)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=6048, event = 851)

3–5 mmol/mol (n=7657, event = 1092)

0–3 mmol/mol (n=23246, event = 3753)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=24259, event = 4292)

3–5 mmol/mol (n=10168, event = 1974)

>5 mmol/mol (n=6363, event = 1461)

Discontinuation (%)

CVD outcomes for no comorbidities population (GLP1 control, values correspond to SGLT2)

Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 38)

3−5 mmol/mol (n=2069, event = 37)

0−3 mmol/mol (n=5420, event = 147)

Predicted HbA1c benefit on GLP1−RA

0−3 mmol/mol (n=4729, event = 139)

3−5 mmol/mol (n=2079, event = 58)

>5 mmol/mol (n=976, event = 47)

Hazards ratio

Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 38)

3−5 mmol/mol (n=2069, event = 37)

0−3 mmol/mol (n=5420, event = 147)

Predicted HbA1c benefit on GLP1−RA

0−3 mmol/mol (n=4729, event = 139)

3−5 mmol/mol (n=2079, event = 58)

>5 mmol/mol (n=976, event = 47)

Hazards ratio

Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 80)

3−5 mmol/mol (n=5327, event = 97)

0−3 mmol/mol (n=16279, event = 382)

Predicted HbA1c benefit on GLP1−RA

0−3 mmol/mol (n=16419, event = 412)

3−5 mmol/mol (n=6763, event = 160)

>5 mmol/mol (n=3028, event = 129)

Hazards ratio

HF outcomes for no comorbidities population (GLP1 control, values correspond to SGLT2)

Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 19)

3–5 mmol/mol (n=2069, event = 20)

0–3 mmol/mol (n=5420, event = 79)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=4729, event = 81)

3–5 mmol/mol (n=2079, event = 33)

>5 mmol/mol (n=976, event = 30)

Hazards ratio

Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 19)

3–5 mmol/mol (n=2069, event = 20)

0–3 mmol/mol (n=5420, event = 79)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=4729, event = 81)

3–5 mmol/mol (n=2079, event = 33)

>5 mmol/mol (n=976, event = 30)

Hazards ratio

Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 42)

3–5 mmol/mol (n=5327, event = 43)

0–3 mmol/mol (n=16279, event = 185)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=16419, event = 208)

3–5 mmol/mol (n=6763, event = 94)

>5 mmol/mol (n=3028, event = 83)

Hazards ratio

CVD outcomes for no CVD population (GLP1 control, values correspond to SGLT2)

Propensity score matching

Overall population (n=18554)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1874, event = 21)

3–5 mmol/mol (n=2102, event = 13)

0–3 mmol/mol (n=5564, event = 61)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=5154, event = 68)

3–5 mmol/mol (n=2347, event = 24)

>5 mmol/mol (n=1513, event = 32)

Propensity score matching + adjusted

Overall population (n=18554)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1874, event = 21)

3–5 mmol/mol (n=2102, event = 13)

0–3 mmol/mol (n=5564, event = 61)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=5154, event = 68)

3–5 mmol/mol (n=2347, event = 24)

>5 mmol/mol (n=1513, event = 32)

Adjusted

Overall population (n=54852)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4320, event = 43)

3–5 mmol/mol (n=5406, event = 41)

0–3 mmol/mol (n=16634, event = 173)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=17142, event = 198)

3–5 mmol/mol (n=7248, event = 79)

>5 mmol/mol (n=4102, event = 71)

HF outcomes for no HF population (GLP1 control, values correspond to SGLT2)

Propensity score matching

Overall population (n=22842)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2074, event = 7)

3–5 mmol/mol (n=2458, event = 10)

0–3 mmol/mol (n=6733, event = 37)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=6524, event = 37)

3–5 mmol/mol (n=3021, event = 22)

>5 mmol/mol (n=2032, event = 31)

Hazards ratio

Propensity score matching + adjusted

Overall population (n=22842)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2074, event = 7)

3–5 mmol/mol (n=2458, event = 10)

0–3 mmol/mol (n=6733, event = 37)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=6524, event = 37)

3–5 mmol/mol (n=3021, event = 22)

>5 mmol/mol (n=2032, event = 31)

Hazards ratio

Adjusted

Overall population (n=66428)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4765, event = 11)

3–5 mmol/mol (n=6188, event = 17)

0–3 mmol/mol (n=19413, event = 62)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=21327, event = 81)

3–5 mmol/mol (n=9219, event = 45)

>5 mmol/mol (n=5516, event = 63)

Hazards ratio